tradingkey.logo
tradingkey.logo
Buscar

Sol Gel Technologies Ltd

SLGL
Añadir a la lista de seguimiento
72.720USD
+4.040+5.88%
Cierre 05/15, 16:00ETCotizaciones retrasadas 15 min
236.00MCap. mercado
PérdidaP/E TTM

Sol Gel Technologies Ltd

72.720
+4.040+5.88%

Más Datos de Sol Gel Technologies Ltd Compañía

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Información de Sol Gel Technologies Ltd

Símbolo de cotizaciónSLGL
Nombre de la empresaSol Gel Technologies Ltd
Fecha de salida a bolsaFeb 01, 2018
Director ejecutivo- -
Número de empleados34
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 01
DirecciónGolda Meir 7
CiudadNESS-ZIONA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal- -
Teléfono97289313433
Sitio Webhttp://www.sol-gel.com
Símbolo de cotizaciónSLGL
Fecha de salida a bolsaFeb 01, 2018
Director ejecutivo- -

Ejecutivos de Sol Gel Technologies Ltd

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--
Mr. Itai Arkin
Mr. Itai Arkin
Director
Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: sáb., 9 de may
Actualizado: sáb., 9 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
M.Arkin Dermatology, Ltd.
55.68%
Opaleye Management Inc.
14.18%
Great Point Partners, LLC
8.45%
Phoenix Investment and Finances Ltd
6.50%
Arkin (Moshe)
4.41%
Otro
10.77%
Accionistas
Accionistas
Proporción
M.Arkin Dermatology, Ltd.
55.68%
Opaleye Management Inc.
14.18%
Great Point Partners, LLC
8.45%
Phoenix Investment and Finances Ltd
6.50%
Arkin (Moshe)
4.41%
Otro
10.77%
Tipos de accionistas
Accionistas
Proporción
Corporation
55.68%
Hedge Fund
22.83%
Investment Advisor
7.62%
Individual Investor
4.46%
Insurance Company
0.23%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.08%
Otro
8.94%

Participación institucional

Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
39
1.00M
30.93%
-175.34K
2025Q4
35
634.85K
22.79%
-440.31K
2025Q3
35
286.02K
10.27%
-480.14K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Opaleye Management Inc.
383.58K
13.77%
+10.43K
+2.80%
Dec 17, 2025
Phoenix Investment and Finances Ltd
218.22K
7.83%
-28.80K
-11.66%
Sep 30, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Yelin Lapidot Provident Funds Management Ltd
17.75K
0.55%
+17.75K
--
Dec 31, 2025
Menora Mivtachim Insurance Ltd.
7.61K
0.27%
+7.61K
--
Sep 30, 2025
Citadel Advisors LLC
6.20K
0.19%
+6.20K
--
Dec 31, 2025
Raymond James Financial Services Advisors, Inc.
--
0%
-7.81K
-100.00%
Sep 30, 2025
Morgan Stanley & Co. LLC
4.37K
0.16%
-970.00
-18.18%
Sep 30, 2025
Ver más

ETFs relacionados

Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
May 01, 2025
Merger
10→1
Fecha
Fecha ex-dividendo
Tipo
Relación
May 01, 2025
Merger
10→1
KeyAI